These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26139989)
1. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. Mosińska P; Fichna J; Storr M World J Gastroenterol; 2015 Jun; 21(24):7436-42. PubMed ID: 26139989 [TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606 [TBL] [Abstract][Full Text] [Related]
3. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study. Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162 [TBL] [Abstract][Full Text] [Related]
4. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs. Taniguchi S; Yano T; Imaizumi M; Manabe N Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138 [TBL] [Abstract][Full Text] [Related]
5. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial. Nakajima A; Seki M; Taniguchi S J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422 [TBL] [Abstract][Full Text] [Related]
6. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota. Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674 [TBL] [Abstract][Full Text] [Related]
7. Elobixibat for the treatment of constipation. Chedid V; Vijayvargiya P; Camilleri M Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116 [TBL] [Abstract][Full Text] [Related]
9. Elobixibat for the treatment of constipation. Wong BS; Camilleri M Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781 [TBL] [Abstract][Full Text] [Related]
10. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Wong BS; Camilleri M; McKinzie S; Burton D; Graffner H; Zinsmeister AR Am J Gastroenterol; 2011 Dec; 106(12):2154-64. PubMed ID: 21876564 [TBL] [Abstract][Full Text] [Related]
11. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation. Miner PB Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377 [TBL] [Abstract][Full Text] [Related]
12. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial. Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787 [TBL] [Abstract][Full Text] [Related]
13. Review article: Elobixibat: a novel treatment for chronic constipation. Khanna L; Camilleri M Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Chen L; Yao X; Young A; McNulty J; Anderson D; Liu Y; Nystrom C; Croom D; Ross S; Collins J; Rajpal D; Hamlet K; Smith C; Gedulin B Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E68-76. PubMed ID: 21934041 [TBL] [Abstract][Full Text] [Related]
15. Apple juice relieves loperamide-induced constipation in rats by downregulating the intestinal apical sodium-dependent bile acid transporter ASBT. Zhu Q; Iwai R; Okaguchi T; Shirasaka Y; Tamai I Food Funct; 2023 May; 14(10):4836-4846. PubMed ID: 37129213 [TBL] [Abstract][Full Text] [Related]
17. ASBT(SLC10A2): A promising target for treatment of diseases and drug discovery. Yang N; Dong YQ; Jia GX; Fan SM; Li SZ; Yang SS; Li YB Biomed Pharmacother; 2020 Dec; 132():110835. PubMed ID: 33035828 [TBL] [Abstract][Full Text] [Related]
18. Plecanatide (Trulance) for chronic idiopathic constipation. Med Lett Drugs Ther; 2017 Apr; 59(1519):66-68. PubMed ID: 28419073 [No Abstract] [Full Text] [Related]
19. Ileal apical sodium-dependent bile acid transporter protein levels are down-regulated through ubiquitin-dependent protein degradation induced by bile acids. Miyata M; Yamakawa H; Hayashi K; Kuribayashi H; Yamazoe Y; Yoshinari K Eur J Pharmacol; 2013 Aug; 714(1-3):507-14. PubMed ID: 23872411 [TBL] [Abstract][Full Text] [Related]
20. New treatment options for chronic constipation: mechanisms, efficacy and safety. Camilleri M Can J Gastroenterol; 2011 Oct; 25 Suppl B(Suppl B):29B-35B. PubMed ID: 22114755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]